ECM
GNMX icon

Element Capital Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Element Capital Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-124,423
Closed -$165K – 125
2017
Q2 		$165K Buy
+124,423
New +$180K 0.03% 106

Other funds holding GNMX

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
NCMW
Northern Capital Management (Wisconsin) Madison, Wisconsin $373M AUM 11.01% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Element Capital Management's GNMX Position: Q3 2017 in Review

Element Capital Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2017, closing a stake of 124,423 shares — an estimated $165K sold.

Element Capital Management first reported a position in GNMX in Q2 2017 and held it in 1 quarter. The position peaked at $165K in Q2 2017. 49 funds tracked by Wall St. Rank hold GNMX as of Q3 2017.

  • Element Capital Management reported no remaining Aevi Genomic Medicine Inc position as of Q3 2017 after selling out during the quarter.
  • Element Capital Management sold 124,423 Aevi Genomic Medicine Inc shares in Q3 2017, an estimated $165K.
  • Element Capital Management first reported a position in Aevi Genomic Medicine Inc in Q2 2017 and held it in 1 quarter.
  • Element Capital Management's Aevi Genomic Medicine Inc position peaked at $165K in Q2 2017.
  • 49 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2017.

Based on Element Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.